The DOI matches its Crossref record; 18 of the 18 references it cites were found in a registry or an index.
Assessment of the safety of recombinant tissue factor pathway inhibitor in patients with severe sepsis: A multicenter, randomized, placebo-controlled, single-blind, dose escalation study
Abstract
OBJECTIVE: To identify a safe and potentially effective recombinant tissue factor pathway inhibitor (rTFPI) dose for further clinical evaluation in patients with severe sepsis. DESIGN: Prospective, randomized, single-blind, placebo-controlled, dose escalation, multicenter, multinational phase II clinical trial. SETTING: Thirty-eight intensive care units in the United States and Europe. PATIENTS: Two hundred and ten subjects with severe sepsis who received standard supportive care and antimicrobial therapy. INTERVENTIONS: Subjects received a continuous intravenous infusion of placebo or rTFPI at 0.025 or 0.05 mg/kg/hr for 4 days (96 hrs). MEASUREMENTS AND MAIN RESULTS: There were no significant imbalances in demographics, severity of illness, or source of infection in patients randomized to placebo or either dose of rTFPI. A 20% relative reduction in 28-day all-cause mortality was observed when all rTFPI-treated patients were compared with all placebo patients. An improvement in pulmonary organ dysfunction score and in a composite intensive care unit score (pulmonary, cardiovascular, and coagulation) were also noted in the rTFPI-treated patients. Logistic regression modeling indicated a substantial treatment by baseline laboratory international normalized ratio (INR) interaction effect when only treatment and INR were in the model (p =.037) and when baseline Acute Physiology and Chronic Health Evaluation (APACHE II) and log10 interleukin 6 were adjusted for (p =.026). This interaction effect indicates that higher baseline INR is associated with a more pronounced beneficial rTFPI effect. There was no increase in mortality in subjects treated with either dose of rTFPI compared with placebo. Biological activity, as detected by a statistically significant reduction in thrombin-antithrombin complexes (TATc), was noted in the all rTFPI-treated patients compared with those receiving placebo. There were no major imbalances across all treatment groups with respect to safety. The frequency of adverse events (AEs) and severe adverse events (SAEs) was similar among the treatment groups, with a slight increase in SAEs and SAEs involving bleeding in the 0.05 mg/kg/hr rTFPI group. The overall incidence of AEs involving bleeding was 28% of patients in the all placebo group and 23% of patients in the all rTFPI-treated group; a slight but statistically insignificant increase in incidence of SAEs involving bleeding was observed in the all rTFPI group (9%) as compared with the all placebo group (6%; p =.39). CONCLUSIONS: Although the trial was not powered to show efficacy, a trend toward reduction in 28-day all-cause mortality was observed in the all rTFPI group compared with all placebo. This study demonstrates that rTFPI doses of 0.025 and 0.05 mg/kg/hr could be safely administered to severe sepsis patients. Additionally, rTFPI demonstrated bioactivity, as shown by reduction in TATc complexes and interleukin-6 levels. These findings warrant further evaluation of rTFPI in an adequately powered, placebo controlled, randomized trial for the treatment of severe sepsis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Vincent, J. L., Moreno, R., Takala, J., Willatts, S., De Mendonça, A., Bruining, H., Reinhart, C. K., Suter, P. M., & Thijs, L. G. (1996) · Intensive Care Medicine · doi:10.1007/bf01709751 · Cited by 11,674
Efficacy and Safety of Recombinant Human Activated Protein C for Severe Sepsis
Bernard, G. R., Vincent, J.-L., Laterre, P.-F., LaRosa, S. P., Dhainaut, J.-F., Lopez-Rodriguez, A., Steingrub, J. S., Garber, G. E., Helterbrand, J. D., Ely, E. W., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200103083441001 · Cited by 6,132
Structural design and molecular evolution of a cytokine receptor superfamily.
Bazan, J. F. (1990) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.87.18.6934 · Cited by 2,069
Tissue factor pathway inhibitor reduces mortality from Escherichia coli septic shock.
Creasey, A. A., Chang, A. C., Feigen, L., Wün, T. C., Taylor, F. B., & Hinshaw, L. B. (1993) · Journal of Clinical Investigation · doi:10.1172/jci116529 · Cited by 547
Self-citationSEVERE SEPSIS AND SEPTIC SHOCK
Balk, R. A. (2000) · Critical Care Clinics · doi:10.1016/s0749-0704(05)70106-8 · Cited by 277
Disseminated Intravascular Coagulation
de Jonge, E., van der Poll, T., ten Cate, H., & Levi, M. (1999) · Thrombosis and Haemostasis · doi:10.1055/s-0037-1615899 · Cited by 243
Sevinsky, J. R., Rao, L. V., & Ruf, W. (1996) · The Journal of cell biology · doi:10.1083/jcb.133.2.293 · Cited by 206
Endothelial cell function and thrombosis
Pearson, J. D. (1999) · Best Practice & Research Clinical Haematology · doi:10.1053/beha.1999.0028 · Cited by 193
Sandset, P. M., Warn-Cramer, B. J., Rao, L. V., Maki, S. L., & Rapaport, S. I. (1991) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.88.3.708 · Cited by 164
The sirens' songs of confirmatory sepsis trials
Natanson, C., Esposito, C., & Banks, S. M. (1998) · Critical Care Medicine · doi:10.1097/00003246-199812000-00001 · Cited by 146
Cited by
Guidelines for the diagnosis and management of disseminated intravascular coagulation
Levi, M., Toh, C. H., Thachil, J., & Watson, H. G. (2009) · British Journal of Haematology · doi:10.1111/j.1365-2141.2009.07600.x · Cited by 1,119
Abraham, E., Reinhart, K., Opal, S., Demeyer, I., Doig, C., Rodriguez, A. L., Beale, R., Svoboda, P., Laterre, P. F., Simon, S., et al. (2003) · JAMA · doi:10.1001/jama.290.2.238 · Cited by 959
Self-citationJackson, S. P., Darbousset, R., & Schoenwaelder, S. M. (2019) · Blood · doi:10.1182/blood-2018-11-882993 · Cited by 616
Weitz, J. I., Eikelboom, J. W., & Samama, M. M. (2012) · Chest · doi:10.1378/chest.11-2294 · Cited by 527
Wada, H., Thachil, J., Di Nisio, M., Mathew, P., Kurosawa, S., Gando, S., Kim, H. K., Nielsen, J. D., Dempfle, C.-E., Levi, M., et al. (2013) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.12155 · Cited by 454
Metadata
- Authors
- Abraham, E., Reinhart, K., Svoboda, P., Seibert, A., Olthoff, D., Dal Nogare, A., Postier, R., Hempelmann, G., Butler, T., Martin, E., Zwingelstein, C., Percell, S., Shu, V., Leighton, A., & Creasey, A. A.
- Venue
- Critical Care Medicine
- Published
- 2001-11
- Volume
- 29
- Issue
- 11
- Pages
- 2081-2089
- ISSN
- 0090-3493 (ISSN-L)
- OpenAlex
- W2091677130
- Cited by
- 253
- References
- 18
- FWCI
- 20.44
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Assessment of the safety of recombinant tissue factor pathway inhibitor in patients with severe sepsis: A multicenter, randomized, placebo-controlled, single-blind, dose escalation study. https://app.cochat.ai/papers/10.1097/00003246-200111000-00007
- The paper
- Abraham, E., Reinhart, K., Svoboda, P., Seibert, A., Olthoff, D., Dal Nogare, A., Postier, R., Hempelmann, G., Butler, T., Martin, E., Zwingelstein, C., Percell, S., Shu, V., Leighton, A., & Creasey, A. A. (2001). Assessment of the safety of recombinant tissue factor pathway inhibitor in patients with severe sepsis: A multicenter, randomized, placebo-controlled, single-blind, dose escalation study. Critical Care Medicine. https://doi.org/10.1097/00003246-200111000-00007
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.